Literature DB >> 19815934

BANK1 functional variants are associated with susceptibility to diffuse systemic sclerosis in Caucasians.

B Rueda1, P Gourh, J Broen, S K Agarwal, C Simeon, N Ortego-Centeno, M C Vonk, M Coenen, G Riemekasten, N Hunzelmann, R Hesselstrand, F K Tan, J D Reveille, S Assassi, F J Garcia-Hernandez, P Carreira, M Camps, A Fernandez-Nebro, P Garcia de la Peña, T Nearney, D Hilda, M A Gónzalez-Gay, P Airo, L Beretta, R Scorza, T R D J Radstake, M D Mayes, F C Arnett, J Martin.   

Abstract

OBJECTIVE: To investigate the possible association of the BANK1 gene with genetic susceptibility to systemic sclerosis (SSc) and its subphenotypes.
METHODS: A large multicentre case-control association study including 2380 patients with SSc and 3270 healthy controls from six independent case-control sets of Caucasian ancestry (American, Spanish, Dutch, German, Swedish and Italian) was conducted. Three putative functional BANK1 polymorphisms (rs17266594 T/C, rs10516487 G/A, rs3733197 G/A) were selected as genetic markers and genotyped by Taqman 5 allelic discrimination assay.
RESULTS: A significant association of the rs10516487 G and rs17266594 T alleles with SSc susceptibility was observed (pooled OR=1.12, 95% CI 1.03 to 1.22; p=0.01 and pooled OR=1.14, 95% CI 1.05 to 1.25; p=0.003, respectively), whereas the rs3733197 genetic variant showed no statistically significant deviation. Stratification for cutaneous SSc phenotype showed that the BANK1 rs10516487 G, rs17266594 T and rs3733197 G alleles were strongly associated with susceptibility to diffuse SSc (dcSSc) (pooled OR=1.20, 95% CI 1.05 to 1.37, p=0.005; pooled OR=1.23, 95% CI 1.08 to 1.41, p=0.001; pooled OR=1.15, 95% CI 1.02 to 1.31, p=0.02, respectively). Similarly, stratification for specific SSc autoantibodies showed that the association of BANK1 rs10516487, rs17266594 and rs3733197 polymorphisms was restricted to the subgroup of patients carrying anti-topoisomerase I antibodies (pooled OR=1.20, 95% CI 1.02 to 1.41, p=0.03; pooled OR=1.24, 95% CI 1.05 to 1.46, p=0.01; pooled OR=1.26, 95% CI 1.07 to 1.47, p=0.004, respectively).
CONCLUSION: The results suggest that the BANK1 gene confers susceptibility to SSc in general, and specifically to the dcSSc and anti-topoisomerase I antibody subsets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19815934      PMCID: PMC2975737          DOI: 10.1136/ard.2009.118174

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  20 in total

Review 1.  Criteria for the classification of early systemic sclerosis.

Authors:  E C LeRoy; T A Medsger
Journal:  J Rheumatol       Date:  2001-07       Impact factor: 4.666

2.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis.

Authors:  E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim
Journal:  J Rheumatol       Date:  1988-02       Impact factor: 4.666

3.  BANK negatively regulates Akt activation and subsequent B cell responses.

Authors:  Yuichi Aiba; Tetsuo Yamazaki; Takaharu Okada; Kumiko Gotoh; Hideki Sanjo; Masato Ogata; Tomohiro Kurosaki
Journal:  Immunity       Date:  2006-03       Impact factor: 31.745

4.  The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype.

Authors:  B Rueda; J Broen; C Simeon; R Hesselstrand; B Diaz; H Suárez; N Ortego-Centeno; G Riemekasten; V Fonollosa; M C Vonk; F H J van den Hoogen; J Sanchez-Román; M A Aguirre-Zamorano; R García-Portales; A Pros; M T Camps; M A Gonzalez-Gay; M J H Coenen; P Airo; L Beretta; R Scorza; J van Laar; M F Gonzalez-Escribano; J L Nelson; T R D J Radstake; J Martin
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

5.  BANK regulates BCR-induced calcium mobilization by promoting tyrosine phosphorylation of IP(3) receptor.

Authors:  Kazumasa Yokoyama; I-hsin Su Ih; Tohru Tezuka; Tomoharu Yasuda; Katsuhiko Mikoshiba; Alexander Tarakhovsky; Tadashi Yamamoto
Journal:  EMBO J       Date:  2002-01-15       Impact factor: 11.598

Review 6.  Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance.

Authors:  Eduardo J Cepeda; John D Reveille
Journal:  Curr Opin Rheumatol       Date:  2004-11       Impact factor: 5.006

Review 7.  Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.

Authors:  Shinichi Sato; Manabu Fujimoto; Minoru Hasegawa; Kazuhiko Takehara; Thomas F Tedder
Journal:  Mol Immunol       Date:  2004-11       Impact factor: 4.407

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Study of functional variants of the BANK1 gene in rheumatoid arthritis.

Authors:  Gisela Orozco; Anna-Karin Abelson; Miguel A González-Gay; Alejandro Balsa; Dora Pascual-Salcedo; Antonio García; Benjamín Fernández-Gutierrez; Ingemar Petersson; Bernardo Pons-Estel; Alicia Eimon; Sergio Paira; Hugo R Scherbarth; Marta Alarcón-Riquelme; Javier Martín
Journal:  Arthritis Rheum       Date:  2009-02

10.  Systemic and cell type-specific gene expression patterns in scleroderma skin.

Authors:  Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-06       Impact factor: 11.205

View more
  45 in total

Review 1.  Unraveling the genetic component of systemic sclerosis.

Authors:  José Ezequiel Martín; Lara Bossini-Castillo; Javier Martín
Journal:  Hum Genet       Date:  2012-01-05       Impact factor: 4.132

Review 2.  Personalized medicine in systemic sclerosis: facts and promises.

Authors:  Rucsandra Dobrota; Carina Mihai; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2014-06       Impact factor: 4.592

Review 3.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

4.  Decreased CD22 expression and intracellular signaling aberrations in B cells of patients with systemic sclerosis.

Authors:  Konstantinos Melissaropoulos; Stamatis-Nick Liossis
Journal:  Rheumatol Int       Date:  2018-06-04       Impact factor: 2.631

Review 5.  Genetics of systemic sclerosis.

Authors:  Lara Bossini-Castillo; Elena López-Isac; Maureen D Mayes; Javier Martín
Journal:  Semin Immunopathol       Date:  2015-06-02       Impact factor: 9.623

Review 6.  The genetics of scleroderma: looking into the postgenomic era.

Authors:  Maureen D Mayes
Journal:  Curr Opin Rheumatol       Date:  2012-11       Impact factor: 5.006

Review 7.  Genetics of scleroderma: implications for personalized medicine?

Authors:  Shervin Assassi; Timothy R D J Radstake; Maureen D Mayes; Javier Martin
Journal:  BMC Med       Date:  2013-01-11       Impact factor: 8.775

Review 8.  Genetics, Epigenetics, and Genomics of Systemic Sclerosis.

Authors:  Gloria Salazar; Maureen D Mayes
Journal:  Rheum Dis Clin North Am       Date:  2015-05-20       Impact factor: 2.670

9.  Genome-wide association study of working memory brain activation.

Authors:  Gabriëlla A M Blokland; Angus K Wallace; Narelle K Hansell; Paul M Thompson; Ian B Hickie; Grant W Montgomery; Nicholas G Martin; Katie L McMahon; Greig I de Zubicaray; Margaret J Wright
Journal:  Int J Psychophysiol       Date:  2016-09-23       Impact factor: 2.997

Review 10.  Molecular and cellular basis of scleroderma.

Authors:  Beate Eckes; Pia Moinzadeh; Gerhard Sengle; Nico Hunzelmann; Thomas Krieg
Journal:  J Mol Med (Berl)       Date:  2014-07-18       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.